Advertisement

Topics

FDA Accepts Otsuka's Resubmission to Support a Regulatory Review of Tolvaptan in the Treatment of ADPKD

07:00 EST 9 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Tolvaptan has been studied in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) in a clinical trial program which included more than 3,165 trial participants exposed to at least one dose of tolvap...

Other Sources for this Article

Otsuka Contacts
(Media outside the U.S)
Otsuka Pharmaceutical Co., Ltd.
Jeffrey Gilbert, 81-3-6361-7379
Leader, Pharmaceutical Public Relations
Gilbert.jeffrey@otsuka.jp
or
(Media in the U.S.)
Otsuka America Pharmaceutical, Inc.
Melanie Deck, 1-609-535-9032
Corporate Communications
melanie.deck-cw@otsuka-us.com
or
(Investors)
Otsuka Holdings Co., Ltd.
Yoko Ishii, 81-3-6361-7411
Ishiiyo@Otsuka.jp

NEXT ARTICLE

More From BioPortfolio on "FDA Accepts Otsuka's Resubmission to Support a Regulatory Review of Tolvaptan in the Treatment of ADPKD"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Endocrinology
Diabetes Diabetes Endocrine Obesity Oxycontin Renal Disease Thyroid Disorders Endocrinology is the study of the endocrine glands and the hormones that they secrete (Oxford Medical Dictionary). There are several groups of h...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...